

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)

ANNOUNCEMENT PURSUANT TO RULE 13.10 OF THE LISTING RULES

This announcement is made by Genscript Biotech Corporation (the “**Company**,” together with its subsidiaries, the “**Group**”) at the request of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) pursuant to Rule 13.10 of the Rules Governing the Listing of Securities on the Stock Exchange.

The board of directors of the Company (the “**Board**”) has noted the increase in the price and trading volume of the shares of the Company (the “**Shares**”) today. The Board wishes to provide the shareholders of the Company (the “**Shareholders**”) and potential investors with the following update on recent business developments of the Group.

The Company has entered into an agreement to join Lilly TuneLab™ (“**TuneLab**”) (the “**Agreement**”), a collaborative AI-enabled (AI/ML) drug discovery platform created by Eli Lilly and Company (“**Lilly**”), a multinational pharmaceutical company listed on the New York Stock Exchange (stock code: LLY). Under the Agreement, the Group will offer preferred-rate wet lab services to TuneLab member companies to generate experimental data and translate AI-generated predictions into biological evidence.

The Board notes the Agreement further expands the Group’s engagement with the rapidly growing AI-enabled drug discovery ecosystem and is aligned with its strategy of supporting biopharmaceutical innovation through integrated research and development solutions. The Board further confirms that the Agreement does not constitute inside information of the Company under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

Having made such enquiries with respect to the Company as are reasonable in the circumstances, the Board confirms that, save as disclosed in this announcement, as of the time of this announcement, it is not aware of any reasons for the movements in the price and trading volume of the Shares, nor is it aware of any inside information that needs to be disclosed under Part XIVA of the SFO.

The Shareholders and potential investors of the Company are advised to carefully consider all relevant investment information and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
Robin Meng
Chairman and Executive Director

Hong Kong, 17 September 2026

*As at the date of this announcement, the executive Directors are Mr. Jiange Meng (“**Mr. Robin Meng**”), Dr. Fangliang Zhang (“**Dr. Frank Zhang**”), Dr. Li Zhu and Ms. Ye Wang (“**Ms. Sally Wang**”); and the independent non-executive Directors are Mr. Yiu Leung Andy Cheung (“**Mr. Andy Cheung**”), Mr. Jiuan Pan (“**Mr. Ethan Pan**”), Dr. John Quelch, Dr. Ross Grossman, and Dr. Chenyang Shi (“**Dr. Victor Shi**”).*